Clinical trials: Genetic Mutation
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai
Colorectal Cancer, Adenomatous Polyps
Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China
The primary objective is to determine the diagnostic sensitivity and specificity of the newly developed multitarget FIT-DNA Colorectal Cancer (CRC) screening test (ColoClear) for detecting advanced neoplasia (including colorectal…
- Conditions
- Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
- Trial name
- CLEAR-C (NCT04287335)
- Testing
- Multitarget stool FIT-DNA test - ColoClear, FIT, Colonoscopy
- Where
- 8 sites in China
- Volunteers
- 4,758 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC…
- Trial name
- NCT04426825
- Testing
- Atezolizumab, Bevacizumab
- Where
- 10 sites in China
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
This is a multicenter, randomized, controlled, phase III study.
- Trial name
- ACROSS2 (NCT04500717)
- Testing
- Almonertinib, Almonertinib plus carboplatin and pemetrexed
- Where
- 5 sites in China
- Volunteers
- 460 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Gene Mutation, Gastric Cancer
CTNNA1 Familial Expansion Study
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
- Conditions
- Cancer Gene Mutation, Gastric Cancer, Breast Cancer
- Trial name
- CAFÉ (NCT05126290)
- Testing
- Collection of personal and family history from CAFÉ Study participants
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Familial Mediterranean Fever
Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission
Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g.
- Trial name
- NCT00323440
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Non Small Cell Lung Cancer, EGFR Gene Mutation
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
This study is a single-center, prospective, single-arm study of the efficacy of double-dose Furmonertinib in the treatment of patients with slow Osimertinib-resistant non-small cell lung cancer, mainly in patients with advanced…
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non-small Cell Lung Cancer Stage IV
- Trial name
- NCT06117644
- Testing
- Furmonertinib
- Volunteers
- 30 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
EGFR, Non-Small Cell Lung Cancer
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
- Conditions
- EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed
- Trial name
- NCT06755684
- Testing
- Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peng Zhang
Non-small Cell Lung Cancer (NSCLC)
AUY922 in Patient With Stage IV NSCLC
This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.
- Trial name
- NSCLC (NCT01922583)
- Testing
- AUY922
- Where
- 3 sites in Taiwan
- Volunteers
- 31 people
- Sponsor
- National Taiwan University Hospital
Lamin A/C Gene Mutation, Dilated Cardiomyopathy, Familial
The Deep Phenotype of Lamin A/C Cardiomyopathy
This study seeks to discover clinically useful tests to improve the diagnosis of a rare and serious heart muscle disease caused by mutations in a gene called 'Lamin'.
- Trial name
- NCT03860454
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University College, London
Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22)
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
The goal of this clinical trial is to learn if avapritinib combined with standard induction therapy works to treat newly diagnosed adult acute myeloid leukemia (AML) patients with KIT mutations and t(8;21)(q22;q22.1)…
- Conditions
- Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation, Avapritinib
- Trial name
- NCT07028073
- Testing
- Group A (FIT): Avapritinib + IA regimen, Group B (UNFIT): Avapritinib + VA regimen
- Where
- China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin…
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05241873
- Testing
- BLU-451, Carboplatin, Pemetrexed
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Blueprint Medicines Corporation
Covid19
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1.
- Trial name
- COVSP-BCG (NCT03305341)
- Testing
- COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Metastatic Melanoma
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well olaparib in combination with pembrolizumab works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT04633902
- Testing
- Olaparib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Advanced Solid Tumor, Metastatic Solid Tumor
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
- Trial name
- NCT05639751
- Testing
- PRT3789, Docetaxel
- Where
- 32 sites in United States, France and 3 more
- Volunteers
- 135 people
- Sponsor
- Prelude Therapeutics Incorporated
Prostate Cancer, Prostate Carcinoma
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
This is a multi-center, single-arm, prospective study to assess the efficacy and safety of Olaparib in men with newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) who carried homologous recombination repair…
- Conditions
- Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- PROspect (NCT05262608)
- Testing
- Olaparib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ciliary Motility Disorders, Primary Ciliary Dyskinesia
Nasal Nitric Oxide Across Mutations in Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by dysfunction of motile cilia associated with recurrent infections of the airways, laterality defects (Situs inversus totalis in about 50% of cases) and…
- Trial name
- nNO_PCD (NCT04949308)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University Hospital Muenster
Neoplasms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion).
- Trial name
- NCT06884618
- Testing
- RO7673396
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 405 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
- Trial name
- NCT01646450
- Testing
- Icotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Astrocytic Tumor, Oligodendroglial Tumor
Study of How Safe and Effective Tarlatamab is in Brain Cancers
This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.
- Trial name
- NCT06776250
- Testing
- Tarlatamab
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.